Skip to main content

POSTPARTUM HEMORRHAGE

Postpartum Hemorrhage

Postpartum hemorrhage is blood loss of > 500 mL during or immediately after the 3rd stage of labor in a vaginal delivery or > 1000 mL in a cesarean delivery. Diagnosis is clinical. Treatment depends on etiology of the hemorrhage.

Causes of postpartum hemorrhage :

> Uterine atony (the most common)
> Lacerations of the genital tract
> Extension of an episiotomy
> Uterine rupture
> Bleeding disorders
> Retained placental tissues
> Hematoma
> Uterine inversion
>Subinvolution (incomplete involution) of the placental site (which usually occurs early but may occur as late as 1 mo after delivery)


Risk factors for uterine atony include uterine overdistention (caused by multifetal pregnancy, polyhydramnios, or an abnormally large fetus), prolonged or dysfunctional labor, grand multiparity (delivery of ≥ 5 viable fetuses), relaxant anesthetics, rapid labor, and chorioamnionitis.

Uterine fibroids may contribute to postpartum hemorrhage. A history of prior postpartum hemorrhage may indicate increased risk.



Treatment

Ø Removal of retained placental tissues and repair of genital lacerations Uterotonics (eg, oxytocin , prostaglandins)
Ø Sometimes surgical procedures


Ø Intravascular volume is replenished with 0.9% saline up to 2 L IV; blood transfusion is used if this volume of saline is inadequate. Hemostasis is attempted by bimanual uterine massage and IV oxytocin infusion, and the uterus is explored for lacerations and retained placental tissues. The cervix and vagina are also examined; lacerations are repaired. Bladder drainage via catheter can sometimes reduce uterine atony.

Ø 15-Methyl prostaglandin F2 α250 μg IM q 15 to 90 min up to 8 doses or methylergonovine 0.2 mg IM q 2 to 4 h (which may be followed by 0.2 mg po tid to qid for 1 wk) should be tried if excessive bleeding continues during oxytocin infusion; during cesarean delivery, these drugs may be injected directly into the myometrium. Prostaglandins should be avoided in women with asthma; methylergonovine should be avoided in women with hypertension. Sometimes misoprostol 800 to 1000 μg rectally can be used to increase uterine tone.

Ø Uterine packing or placement of a Bakri balloon can sometimes provide tamponade. This silicone balloon can hold up to 500 mL and withstand internal and external pressures of ≤ 300 mm Hg. If hemostasis cannot be achieved, surgical placement of a B-Lynch suture (a suture used to compress the lower uterine segment via multiple insertions), hypogastric artery ligation, or hysterectomy may be required. Uterine rupture requires surgical repair.

Blood products are transfused as necessary, depending on the degree of blood loss and clinical evidence of shock. Infusion of factor VIIa (50 to 100 μg/kg, as a slow IV bolus over 2 to 5 min) can produce hemostasis in women with severe life-threatening hemorrhage. The dose is given q 2 to 3 h until hemostasis occurs.


Prevention

Ø Predisposing conditions (eg, uterine fibroids, polyhydramnios, multifetal pregnancy, a maternal bleeding disorder, history of puerperal hemorrhage) are identified antepartum and, when possible, corrected. If women have an unusual blood type, that blood type is made available. Careful, unhurried delivery with a minimum of intervention is always wise.

Ø After placental separation, oxytocin 10 units IM or dilute oxytocin infusion (10 or 20 units in 1000 mL of an IV solution at 125 to 200 mL/h for 1 to 2 h) usually ensures uterine contraction and reduces blood loss. After the placenta is delivered, it is thoroughly examined for completeness; if it is incomplete, the uterus is manually explored and retained fragments are removed. Rarely, curettage is required. Uterine contraction and amount of vaginal bleeding must be observed for 1 h after completion of the 3rd stage of labor.

Prepared and modified by MD. Niamul Hasan , MBBS Final Year BMCH

Comments

Popular posts from this blog

Monoclonal Antibody Targets, Kills Leukemia Cells

Monoclonal Antibody Targets, Kills Leukemia Cells  Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells The findings, published in the online Early Edition of the Proceedings of the National Academy of Sciences on March 25, 2013 represent a potential new therapy for treating at least some patients with CLL, the most common type of blood cancer in the United States. CLL cells express high levels of a cell-surface glycoprotein receptor called CD44. Principal investigator Thomas Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, and colleagues identified a monoclonal antibody called RG7356 that specifically targeted CD44 and was directly toxic to cancer cells, but had little effect on normal B cells. Moreover, they found RG7356 induced CLL cells that expressed the protein ZAP-70 to undergo apoptosis or programmed cell death.

Stem Cell Treatment May Become Option to Treat Nonhealing Bone Fractures

Stem Cell Treatment May Become Option to Treat Non healing Bone Fractures Stem cell therapy enriched with a bone-regenerating hormone, insulin-like growth factor-I (IGF-I), can help mend broken bones in fractures that are not healing normally, a new animal study finds. The results are being presented at The Endocrine Society's 93rd Annual Meeting in Boston. A deficiency of fracture healing is a common problem affecting an estimated 600,000 people annually in North America, according to the principal investigator, Anna Spagnoli, MD, associate professor of pediatrics and biomedical engineering at the University of North Carolina at Chapel Hill. "This problem is even more serious," Spagnoli said, "in children with osteogenesis imperfecta, or brittle bone disease, and in elderly adults with osteoporosis, because their fragile bones can easily and repeatedly break, and bone graft surgical treatment is often not successful or feasible" Fractures that do not hea

Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic Retinopathy

Although vascular endothelial growth factor (VEGF) is a primary mediator of retinal angiogenesis, VEGF inhibition alone is insufficient to prevent retinal neovascularization. Hence, it is postulated that there are other potent ischemia-induced angiogenic factors. Erythropoietin possesses angiogenic activity, but its potential role in ocular angiogenesis is not established. METHODS We measured both erythropoietin and VEGF levels in the vitreous fluid of 144 patients with the use of radioimmunoassay and enzyme-linked immunosorbent assay. Vitreous proliferative potential was measured according to the growth of retinal endothelial cells in vitro and with soluble erythropoietin receptor. In addition, a murine model of ischemia-induced retinal neovascularization was used to evaluate erythropoietin expression and regulation in vivo. RESULTS The median vitreous erythropoietin level in 73 patients with proliferative diabetic retinopathy was significantly higher than that in 71 patients with